Gain Therapeutics (GANX) Operating Income (2020 - 2026)

Gain Therapeutics has reported Operating Income for 7 years, with the latest figure at -$4.7 million in Q2 2026.

• On a quarterly basis, Operating Income rose 8.01% year-over-year to -$4.7 million in Q2 2026; TTM through Jun 2026 was -$19.3 million, a 11.82% decrease from a year earlier, with the FY2025 full-year figure at -$18.7 million, up 8.06% from the prior year.
• Operating Income was -$4.7 million for Q2 2026 at Gain Therapeutics, up from -$5.4 million in the prior quarter.
• The five-year high for Operating Income was -$3.3 million in Q1 2022, with the low at -$8.2 million in Q2 2024.
• Average Operating Income over 5 years is -$5.0 million, with a median of -$4.7 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Operating Income sank 59.03% in 2023, then jumped 37.8% in 2025.
• Over 5 years, Operating Income stood at -$4.6 million in 2022, then gained by 3.38% to -$4.4 million in 2023, then gained by 24.42% to -$3.3 million in 2024, then tumbled by 34.07% to -$4.5 million in 2025, then declined by 4.83% to -$4.7 million in 2026.
• The last three Operating Income figures came in at -$4.7 million (Q2 2026), -$5.4 million (Q1 2026), and -$4.5 million (Q4 2025), per Business Quant data.